genXone

NGS sequencing & microbiome · Microbiome, infectious dx

Overview

Long-read (Oxford Nanopore) sequencing services and microbiome diagnostics; spun out of Inno-Gene.

What they do

genXone S.A. is a Polish genomics company that was Poland's first certified commercial partner of Oxford Nanopore Technologies. It provides next-generation, long-read nanopore sequencing services and develops its own laboratory protocols and bioinformatics tools for applications across genetic diagnostics, microbiome research, food, veterinary and agricultural testing. The company was spun out of Inno-Gene.

Lead program & status

genXone's core commercial offering combines Oxford Nanopore sequencing with microbiome diagnostics (including gut-microbiome profiling) and infectious-disease and metagenomic testing. Its team specialises in microbiome analysis, metagenomics, RNA, nutrigenomics and molecular ecology. Since 2021 genXone shares have traded on the Warsaw Stock Exchange's NewConnect alternative market under the ticker GX1, funding expansion of its sequencing and diagnostics services.

Why it matters

Long-read nanopore sequencing enables analyses that short-read platforms struggle with, from full-length 16S microbiome characterisation to complex metagenomes. As an established ONT partner in Poland, genXone gives regional researchers and clinics local access to long-read sequencing and bioinformatics rather than relying on foreign service providers.

FAQ

What sequencing technology does genXone use?

genXone uses Oxford Nanopore long-read sequencing and was Poland's first certified commercial Oxford Nanopore partner.

Is genXone listed on a stock exchange?

Yes. genXone has traded on the Warsaw Stock Exchange NewConnect market since 2021 under the ticker GX1.

Where did genXone come from?

genXone was spun out of the Polish genomics group Inno-Gene.

Company website / source ↗ Open the interactive map →